COSCIENS Biopharma Inc T.CSCI

PGX thin strips and Macimorelin?

[prophetoffactz]

Perplexity Ai:

Ceapro's PGX technology could potentially help improve the delivery of macimorelin, offering several potential advantages:

Improved Bioavailability and Dosing

Ceapro's PGX technology has demonstrated the ability to create thin strips that dissolve instantly on the tongue. This delivery method could offer advantages for macimorelin administration:

• Enhanced absorption: The rapid dissolution of PGX-processed thin strips could lead to faster and more efficient absorption of macimorelin through the oral mucosa.
• Convenient dosing: Thin strips would eliminate the need to swallow pills with water, making administration easier for patients.
• Potential for precise dosing: The uniform nature of thin strips could allow for more accurate dosing compared to oral solutions or tablets.

Increased Drug Loading and Efficacy

PGX processing has shown the ability to significantly increase the amount of drug or bioactive that can be loaded into a dose

For macimorelin, this could potentially:

• Allow for higher drug concentrations in a single dose
• Improve overall efficacy of the treatment
• Potentially reduce the number of doses required

Versatile Formulation Options

The PGX technology offers flexibility in formulation:

• Controlled release: PGX can enable the creation of fast or slow-release versions of bioactives, which could be beneficial for optimizing macimorelin's pharmacokinetics.
• Combination possibilities: The technology might allow for the incorporation of other beneficial ingredients alongside macimorelin in a single dosage form.

Potential for New Indications

While macimorelin is currently used for diagnosing adult growth hormone deficiency, improved delivery via PGX technology could potentially:

• Expand its use in other diagnostic applications
• Enable exploration of therapeutic uses, such as the treatment of cancer cachexia, which has been investigated in early clinical trials.

By leveraging Ceapro's PGX technology, there is potential to enhance macimorelin's effectiveness, patient compliance, and overall clinical utility. However, extensive research and clinical trials would be necessary to validate these potential benefits and ensure safety and efficacy of any new formulation.